$28.95
0.07% day before yesterday
Nasdaq, May 30, 10:12 pm CET
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Legend Biotech Corp - ADR Stock price

$28.95
-6.00 17.17% 1M
-14.36 33.16% 6M
-3.59 11.03% YTD
-14.38 33.19% 1Y
-13.78 32.25% 3Y
-8.05 21.76% 5Y
-8.05 21.76% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.02 0.07%
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Key metrics

Market capitalization $5.33b
Enterprise Value $4.69b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.44
P/S ratio (TTM) P/S ratio 7.32
P/B ratio (TTM) P/B ratio 10.47
Revenue growth (TTM) Revenue growth 112.46%
Revenue (TTM) Revenue $728.30m
EBIT (operating result TTM) EBIT $-237.93m
Free Cash Flow (TTM) Free Cash Flow $-273.17m
Cash position $1.01b
EPS (TTM) EPS $-0.59
P/E forward negative
P/S forward 5.23
EV/Sales forward 4.60
Short interest 7.90%
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Legend Biotech Corp - ADR forecast:

23x Buy
96%
1x Hold
4%

Analyst Opinions

24 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
96%
Hold
4%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
728 728
112% 112%
100%
- Direct Costs 251 251
54% 54%
34%
477 477
166% 166%
66%
- Selling and Administrative Expenses 301 301
39% 39%
41%
- Research and Development Expense 415 415
4% 4%
57%
-215 -215
47% 47%
-30%
- Depreciation and Amortization 23 23
13% 13%
3%
EBIT (Operating Income) EBIT -238 -238
45% 45%
-33%
Net Profit -218 -218
53% 53%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Neutral
GlobeNewsWire
10 days ago
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology ...
Neutral
Seeking Alpha
19 days ago
Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - Chief Executive Officer Jessie Yeung - Interim Chief Financial Officer Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Gena Wang - Barclays Jess...
Neutral
GlobeNewsWire
19 days ago
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights.
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 2,600
Founded 2014
Website investors.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today